REVIEW ARTICLE

Current concepts on tenogenic differentiation and clinical applications

Yang Liu a, Chun-Wai Suen a, Jin-fang Zhang a, Gang Li a,b,c,d,*

a Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
b Stem Cells and Regenerative Medicine Laboratory, Lui Che Woo Institute of Innovative Medicine, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
c Key Laboratory for Regenerative Medicine, Ministry of Education, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
d The CUHK-ACC Space Medicine Centre on Health Maintenance of Musculoskeletal System, The Chinese University of Hong Kong Shenzhen Research Institute, Shenzhen, China

Received 15 December 2016; received in revised form 21 February 2017; accepted 23 February 2017
Available online 18 March 2017

KEYWORDS
mesenchymal stem cells; tendon derived stem cells; tendon healing; tenogenic differentiation

Summary  Tendon is a tissue that transmits force from muscle to bone. Chronic or acute tendon injuries are very common, and are always accompanied by pain and a limited range of motion in patients. In clinical settings, management of tendon injuries still remains a big challenge. Cell therapies, such as the application of stem cells for tenogenic differentiation, were suggested to be an ideal strategy for clinical translation. However, there is still a lack of specific methods for tenogenic differentiation due to the limited understanding of tendon biology currently. This review focuses on the summary of current published strategies for tenogenic differentiation, such as the application of growth factors, mechanical stimulation, biomaterials, coculture, or induced pluripotent stem cells. Current clinical applications of stem cells for treatment of tendon injuries and their limitations have also been discussed in this review.

© 2017 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Tendon is a tissue that transmits force from muscle to bone. Tendon injuries, such as tendinopathy or acute tendon rupture, are a common type of sports injuries. However, current treatments for tendon injuries are unsatisfactory and limited to the nonsteroidal anti-inflammatory drug injection, physical therapy, or surgery [1–3]. Tendon tissue engineering has been suggested to be a promising approach for tendon repair. Since bone marrow stem cells (BMSCs) or tendon-derived stem cells (TDSCs) have outstanding self-renewal and multidifferentiation ability, it is a well-recognized strategy to apply them in tendon tissue engineering [4,5]. Although many genes are reported to be involved in tendon development, they also express in a wide range of other tissues, such as muscle, bone, and cartilage. Owing to the limited understanding of specific tendon makers and molecular interactions between transcription factors and signalling pathways, there is still a lack of a specific method for tenogenic differentiation. Currently, various protocols have been reported to be able to induce tenogenic differentiation. This review focuses on the summary of currently published strategies for tenogenic differentiation, such as the application of growth factors, mechanical stimulation, biomaterials, coculture with differentiation, such as the application of growth factors, mechanical stimulation, biomaterials, coculture with
differentiation, such as the application of growth factors, mechanical stimulation, biomaterials, coculture with
differentiation, such as the application of growth factors, mechanical stimulation, biomaterials, coculture with
differentiation, such as the application of growth factors, mechanical stimulation, biomaterials, coculture with

Transcription factors of tendon

Currently, Scx, Mohawk (Mkx), and early growth response protein 1 (Egr1) have been identified as the transcription factors for tendon development [9,20,21]. Scx, a basic helix–loop–helix transcription factor, is a relatively specific marker of tendon/ligament lineage and has been reported to be induced at the earliest stage during tendon development [22–24]. Mice with Scx knockdown (Scx
to induce tenogenic differentiation. This review focuses on the summary of currently published strategies for tenogenic differentiation, such as the application of growth factors, mechanical stimulation, biomaterials, coculture with another cell source, TDSCs, or BMSCs. An advanced understanding of the current strategies on tenogenic differentiation would be beneficial for tendon tissue engineering and its clinical translation in the future.

Tendon biology

Tendon and associated extracellular matrix markers

Tendon formation relies on the combination of the transcription factors, growth factors, and mechanical stimulation during development [6]. In normal tendon, the primary unit of the tendon is the fibre that made up of collagen fibrils with tendon cells residing inside [6]. The dry mass of human tendons is about 30% of the total tendon mass, with water accounting for 70% [7]. From the dry mass of tendon, collagen type I accounts for 65–80%, and elastin takes up about 2% [7,8]. Collagen provides elasticity to the tendon, which is mainly made up of type I collagen (Col1) and a small amount of other collagens, such as types III, IV, V, and VI [9]. The extracellular matrix (ECM) functions as the organizer for collagen fibril assembly [5,10,11], and it is composed of proteoglycan, glycoproteins, and other small molecules. Decorin (Dcn) and biglycan (Bgn) are the common small leucine-rich proteoglycans in tendons that help organize the collagen fibre bundles. Targeted knockout of certain proteoglycan can lead to abnormal collagen fibrils in tendons and impair their mechanical properties [12–14]. Other common proteoglycans are fibromodulin and lumican. It was reported that Tenascin-C (Tn-C), a glycoprotein, is regulated by mechanical loading and is upregulated in patients with tendinopathy [15,16]. Moreover, Tn-C also participates in collagen fibre alignment and orientation [7]. Particularly, Tenomodulin (Tnmd) is a type II transmembrane glycoprotein containing a C-terminal antiangiogenic domain, and it is necessary for tenocyte proliferation and tendon maturation [17,18]. The expression of Tnmd is positively regulated by Scleraxis (Scx) [19]. Mice with loss of Tnmd expression showed impaired tenocyte proliferation, reduced tenocyte density, and increased maximal and greater variation of fibril diameters [18].

Tendon-derived stem cells

Bi et al [5] first identified and characterized tendon stem cells in tendons from human and mice, followed by Rui et al [31] in isolating and identifying TDSCs from rat tendon. TDSCs showed multipotent and self-renewal capacities, and they have been suggested as an ideal cell source for tendon tissue engineering. Moreover, it is also found that TDSCs have higher Tnmd, Scx, Col1, Dcn, Bgn expression; osteogenic differentiation; and chondrogenic differentiation abilities when compared with BMSCs [32].
Current strategies on tenogenic differentiation

In the past 2 decades, many studies and reviews have been performed to foster the understandings on tendon development [30,33,34]. It has been recognized that tendon development relies on both biological and biomechanical stimulation [29,30,35]. Embryological studies have revealed that TGF-β, bone morphogenetic protein (BMP), fibroblast growth factor (FGF), and Wnt signalling pathways were involved during the differentiation of skeletal progenitor cells [23,29,35–38]. It was additionally suggested that the divergent differentiation of progenitors are dependent on the temporal coordination of those signals, rather than solely via an individual signalling pathway in an embryonic digit model [23,29]. Apart from the biological factors, mechanical stimulation is also necessary for tendon development, especially during the late stage of collagen maturation [29]. Applications of mechanical stimulation on TDSCs or BMSCs were also reported to promote tenogenic differentiation. Furthermore, discovery of novel biomaterials, using the coculture strategy, or application of induced pluripotent stem cells (iPSCs) was also suggested to be considered for tendon tissue engineering. In this review, we focus on the summary of the currently published strategies for the above subtopics on tenogenic differentiation and their current clinical applications.

Literature search

A comprehensive literature review was performed to obtain experimental studies on the following topics for tenogenic differentiation and clinical applications. We conducted a literature search using the PubMed search engine with the following terminologies relevant to the topic: “tenogenic differentiation”, “GDF and tenogenic differentiation”, “BMP and tenogenic differentiation”, “FGF and tenogenic differentiation”, “TGF-β and tenogenic differentiation”, “Wnt and tenogenic differentiation”, “decellularized matrix and tenogenic differentiation”, “coculture and tenogenic differentiation”, “iPSCs and tenogenic differentiation”, “tendon stem cells and tenogenic differentiation”, “bone marrow stem cells and tenogenic differentiation”, “adipose stem cells and tenogenic differentiation”, and “stem cell and tendon”. Studies published in the recent 10 years were screened by title first, and then by the abstract, to confirm whether relevant information was provided. Articles shown in the reference list in published systematic reviews not found in the PubMed were also included.

Growth factors

TGF-β ligands

TGF-β signalling plays a key role in tendon formation and has been suggested to be a potent inducer of the tendon transcription factor Scx [38]. In embryos with TGF-β signalling disruption (TGF-β2−/− or TGF-β3−/−), loss of tendons and ligaments in limbs, trunk, tail, and head was observed, indicating that TGF-β2 and TGF-β3 might mediate new tendon cells towards tenogenic differentiation. As per in vitro studies, the effects of TGF-β on promoting tenogenic differentiation were well reported by enhancing tenogenic gene expression (Scx, Tnmd, and Egr1) and ECM production [38–40]. Recently, a stepwise protocol using TGF-β1 to initiate tenogenic differentiation, followed by a combination of TGF-β/connexin tissue growth factor (CTGF) to further maintain the teno lineage, was reported to better promote tenogenic differentiation [40]. As observed in in vivo studies, the induced BMSCs could promote neotendon formation, patellar tendon repair, and increased mechanical properties, indicating its potential application in clinical treatment. However, there is also the controversy that TGF-β could promote tissue fibrosis by increasing Col1 production and scar formation during injury healing [41], indicating that the application of TGF-β-treated BMSCs was better than the direct injection of TGF-β ligands into the injury site, to avoid excess collagen formation and scarring during injury healing. By the transcriptome analysis of mouse limb tendon cells during development, Havis et al [39] found that TGF-β signalling was sufficient to drive mesodermal stem cells towards tendon lineage via the intracellular Smad2/3 pathway. It is also reported that mature tendons in Smad3−/− mice showed crimped fibres, lower tenogenic gene expression [42], and impaired tendon healing [43]. However, fewer effects of Smad3 on tenogenic differentiation in BMSCs were reported. Considering the obvious tendon defects in Smad3−/− mice, its effects on BMSCs are warranted to be further studied in the future.

FGF ligands

FGF is a crucial signal for limb outgrowth [44]. Loss of myotomal FGF protein leads to the absence of tendon formation via Myf5 and Myod1 expression [45], and FGF4 was also reported to induce the expression of Egr1 and Egr2, transcription factors expressed in tendons, to help in the maturation of tendon tissues [28]. FGF is also one of the basic components of platelet-rich plasma, which has been reported to promote tendon injury [46]. As observed in vitro studies, FGF2 (also known as bFGF) was mostly shown to promote matrix production (e.g., Col1 and Tn-C) [47–50] or Scx [51,52] in either BMSCs or other stem cell types. According to in vivo studies, FGF2 plantated in the fibrin [53,54] or gelation hydrogel [35] was reported to promote rat tendon healing by increasing collagen production and mechanical strength, indicating its potential for future applications. However, Brown and colleagues [39] reported that FGF4 has no effects on the regulation of tendon-related gene expression in tendon progenitor cells, although it was reported to activate the expression of Egr1 and Egr2 in vivo. Current results support that FGF2 plays a positive role on tenogenic differentiation, compared with FGF4.

BMP (growth differentiation factor) ligands

Growth differentiation factors (GDFs) are a subfamily of the BMPs that are indispensable in skeletal tissue development, such as joint formation, due to their associations with osteogenic or chondrogenic differentiation [37].
GDF5 (also named as BMP14), GDF6 (also named as BMP13), and GDF7 (also named as BMP12) were first reported to promote ectopic neotendon/ligament formation in rats by Wolfman et al. [56]. Tendons in GDF5−/− mice showed weaker mechanical properties, reduced collagen production, and smaller collagen fibrils, and Achilles tendon injury also exhibits a 1–2-week delay in injury healing [36,57,58]. Similarly, defects in joint, ligament, and cartilage formation were observed in mice with GDF6 deficiency [59]. Tail tendons in GDF6-deficient mice showed a lower collagen content, which further contributed to the impaired mechanical property [60]. In mice with GDF7 deficiency, the Achilles tendon in GDF7−/− mice showed a smaller fibril diameter when compared with the wild-type controls, while there was no significant difference in the expression of tendon proteoglycans (Dcn, fibromodulin, lumican, and Bgn). There may be compensating effects in GDF family members during tendon formation, as GDF5 and GDF6 showed a two-fold increase in tendons of GDF5−/− mice [61].

In in vitro studies, the role of GDFs in tenogenic differentiation was well summarized by Lui et al. [34] and is not shown in detail in Table 1 except for new studies. The mechanisms of GDFs on promoting tenogenic differentiation may be caused by activating cytoskeleton reorganization signaling (stress fibre formation) [62] or activating the Smad1/5/8 signalling pathway [63]. Considering the osteogenic or chondrogenic differentiation effects of the BMP family, Noggin was suggested to play an essential role in switching from osteogenic or chondrogenic to tenogenic differentiation of stem cells during the development [33].

As observed in in vivo studies, suture coating with GDF5 was reported to promote collagen synthesis and cell migration in tendon fibroblast [64], and promote injury healing by increasing collagen formation and maximal loading in a rat flexor tendon laceration [65]. In a clinical randomized control trial, implantation of recombinant human bone morphogenic protein 12 (rhBMP12) (GDF7)/absorbable collagen sponge was shown to promote rotator cuff injuries in 14 of 16 patients at 1-year follow-up, indicating its safety and potential to promote tendon injury repair in the future [66]. However, there is a lack of conclusion on the effects of GDF6 in tendon injury healing currently. Jelinsky et al. [67] showed that injection of GDF6 or GDF7 on Day 1 after tendon injury could promote injury healing, but no related histology or mechanical testing data were shown. While Gulotta et al. [68] reported that injection of GDF6-overexpressing MSCs (mesenchymal stem cells) could not promote injury healing in a rat supraspinatus tendon repair model, compared with the MSC-only group. Collectively, GDF5 or GDF7 may have potential therapeutic effects on tendon injury. For clinical translation, suture coating with GDFs or combining GDFs with biomaterials could be a potential consideration for tendon injuries.

Wnt ligands

Wnt signalling is essential and plays multiple roles during vertebrate limb development [69]. As a classic signalling pathway on promoting osteogenic differentiation, recent studies also indicated that it plays a role in tendon/ligament formation during embryogenesis [33,35]. In an in vitro study, Miyabara et al. [70] reported that the activation of Wnt/β-catenin signalling could induce Tnmd expression in BMSCs via glycogen synthase kinase-3. It was also reported that Wnt4 and Wnt5a were highly involved in the dynamic loading of tenogenic differentiation [29,71]. However, there are fewer studies showing that ectopic Wnts could promote tenogenic differentiation directly, indicating that it may be one of the signalling pathways involved in tendon development, instead of the pathway that could activate tendon development directly.

Others

Recently, Havis et al. [35] reported that MAPK (Mitogen-activated protein kinase), calcium, Wnt, and Hedgehog signalling were greatly involved in mouse limb tendon development using transcriptomic analysis, in addition to the TGF-β signalling pathway. Our group also found that inhibition of the ERK (Extracellular signal-regulated kinases) signalling pathway could promote tenogenic differentiation via activation of Sx, Col1, Dcn, and Tnmd (unpublished data). Our results are consistent with those of Havis et al. [35] that inhibition of ERK MAPK signalling can activate Sx in mouse limb mesodermal progenitors and mesenchymal stem cells. Moreover, the Hedgehog signalling plays an important role during tendon development via its downstream effector Gli1 [72]. Carbone et al. [73] also reported that Hedgehog signalling is mechanosensitive and active during tendon–bone healing in a rat anterior cruciate ligament reconstruction model.

Connective tissue growth factor

CTGF (also named as CCN2) is important in biological processes such as skeletal development and differentiation [74]. According to in vitro studies, CTGF could upregulate Col1 and Tn-C expression in human BMSCs, and accelerate the formation of fibrosis-like tissue from connective tissue without ectopic mineralization [75]. Particularly, CTGF showed better effects in tendon cells by activating Sx, Tnmd, and other ECM marker expression, compared with that in BMSCs [76,77]. It is also reported that the engineered scaffold-free tendon tissue, produced via CTGF and ascorbic acid-treated TDCs, showed significantly higher Tnmd, Sx, Col1, Dcn, and Thbs4 expression, and augmented tendon repair in both patellar tendon defect [78,79] and anterior cruciate ligament reconstruction models [80]. The basal expression level of Sx in BMSCs was significantly lower than that in TDCs [32]. The limited effects of CTGF on Sx expression in BMSCs indicate that it cannot activate Sx directly. To solve the problem, a stepwise differentiation strategy was suggested by Yin et al. [40]. They first stimulated BMSCs with TGF-β1 to activate the tendon-specific marker expression (e.g., Sx), and then followed by combination with CTGF. The results indicated that the expression of Sx was further activated (as well as that of Tnmd), compared with TGF-β1 only [40]. It is
| Factor | Study types | Species | Cell model | Injury model | Effects | Study level |
|--------|-------------|---------|------------|--------------|---------|-------------|
| **TGF-β signalling pathway** | | | | | | |
| TGF-β2; TGF-β3 [33] | In vivo | Mice | TGF-β2−/−; TGF-β3−/− mice | TGF-β2−/−; TGF-β3−/− | Loss of tendons during development | 3 |
| TGF-β2 [34] | In vitro | Mice | TPC | / | ↑Scx | 2 |
| TGF-β1 + CTGF [40] | In vitro & in vivo | Human | BMSCs | / | ↑Scx, Tnmd, & ECM; ↑mature collagen formation and mechanical properties of new formed tendon | 3 |
| **TGF-β1 antibody [41]** | In vitro & in vivo | Rabbit | Tenocytes | Inject into transected flexor digitorum tendon | ↑Collagen formation; limited range of motion | 2 |
| **Smad3 [42,43]** | In vivo | Mice | Smad3−/− mice | Flexor digitorum longus tendon repair | Tendons showed crimped fibres and ↓Col1 and Tn-C; ↓mechanical properties and ↑collagen formation | 3 |
| **FGF signalling pathway** | | | | | | |
| FGF2 [47] | In vitro | Human | BMSC | / | ↑Col1, Col3, fibronectin at 3 ng/mL | 1 |
| FGF2 [51] | In vitro | Mice | C3H10T1/2/inkjet-based bioprinter | / | ↑Pea3, Erm, Scx | 2 |
| FGF2 [52] | In vitro | / | Patterned with submicron polystyrene fibres | / | ↑Scx expression | 2 |
| FGF2/FGF5 [48] | In vitro | Foals | Umbilical cord blood stem cells/ASCs | / | ↑Tn-C expression in matrix gel | 1 |
| FGF4 [39] | In vitro | Mice | TPCs | / | No effect despite regulation of other genes | 2 |
| FGF2 [54] | In vivo | Rat | In fibrin sealant (100 mg/kg) | Rotator cuff tendon defects | ↑Collagen maturation; mechanical properties | 2 |
| FGF2 [55] | In vivo | Rat | Gelatin hydrogel containing 5 μg of FGF2 | Supraspinatus tendon to insertion sites | ↑Scx, Tnmd; ↑mehanical strength; collagen fibres with an aligned orientation | 3 |
| bFGF (FGF2) [49] | In vivo | Chicken | / | FDP tendons, injected vectors carrying bFGF transgenes | ↑Col1 production and cell proliferation; mechanical strength; ↑fibre arrangement | 2 |
| bFGF (FGF2) [50] | In vivo | Rat | Slow release by an osmotic pump | Chronic supraspinatus tendon lesion | ↑Col1 production | 1 |
| **BMP signalling pathway** | | | | | | |
| GDF5 coating suture [64] | In vitro | Rat | Fibroblast | / | ↑Cell migration; cell proliferation; collagen synthesis | 1 |
### Tenogenic Differentiation and Clinical Applications

| Signalling Pathway | Species | Cell Source | Treatment | Outcome |
|--------------------|---------|-------------|-----------|---------|
| **GDF5 coating suture** | Rabbit | / | Zone II flexor tendon lacerations | †Collagen formation; increase maximal loading |
| **GDF6** | Rat | BMSC with overexpression of GDF6 or BMSC seeded in fibrin sealant | Implant in supraspinatus tendon–bone interface | No significant difference on histology and mechanical properties |
| **rhBMP12 or rhBMP13** | Rat | / | Achilles tendon transaction model | †Rat and quality of tendon repair |
| **rhBMP12** | Human | rhBMP2 in absorbable collagen sponge | Implanted in rotator cuff repair | 1 y follow-up; 14/16 patients with complete healing |
| **GDF7** | Canine | ADSCs | / | †Scx, Tnmd; †Ocn expression; †Smad1/5/8 signalling pathway |
| **Wnt signalling pathway** | Equine | BMSC in collagen gel MSC-seeded collagen gel under mechanical stimulation | / | †Tnmd, Dcn, and Fmod |
| **GSK-3 inhibitor** | Human | Tenocytes seeded in polyglycolic acid long fibres under mechanical stimulation | / | †Wnt5a |
| **Wnt5a** | Human | Canine | / | †Wnt5a |
| **Other signalling pathway** | Rat | ACL reconstruction using a flexor tendon graft with pretension E9.5 mouse limb explants | Indian Hedgehog signalling was active at the healing tendon–bone interface | Inhibition of the ERK/MAPK could †Scx in mouse limb mesodermal progenitors |
| **ERK/MAPK** | Mice | C3H10T1/2 | / | †Scx and ECM gene expression; †collagen formation and mechanical properties |
| **CTGF** | Rat | TDSC | Tendon-like cell sheet implanted in rat patellar tendon defect model | †Scx, Tnmd, Tn-C, Col1 |
| **CTGF + Vc** | Rat | Overexpression of CTGF in TDSCs | / | †Col1, Tn-C; promote fibrosis tissue formation in vivo |
| **CTGF** | Rat | BMSC | Rat calvarial defect model (with CTGF seeded in PLGA microspheres) | †Col1a1, Col3a1, Tnc, Vim, Tnmd, Scx; †dense alignment of collagen fibres and maximal loading |
| **Mechanical stimulation** | Rat | Tendon cells | CTGF seeded in fibrin glue and implanted in patellar tendon defect | Gradual and temporary loss of tensile loading causes reversible loss of Scx expression |
| **Mechanical stretching** | Mice | Adult tenocyte cell line | ScxGFP transgenic mice | (continued on next page) |
| Factor                        | Study types         | Species | Cell model                               | Injury model                                  | Effects                                                                 | Study level |
|------------------------------|---------------------|---------|------------------------------------------|-----------------------------------------------|-------------------------------------------------------------------------|-------------|
| Mechanical stretching        | In vitro & in vivo  | Mice    | TDSC with low/high mechanical stretching | Mice underwent MTR (4%)/ITR (8%) treadmill running | †Col1, Tnmd; with no effects on nontendon marker gene expression in LTR treatment | 2           |
| [82]                         |                     |         |                                          |                                               | †Runx2, Dlx5, Alp, and Col1A1 at 1 Hz, 8%                              |             |
| Mechanical stretching        | In vitro            | Mice    | TPCS                                     | /                                             | †Tenogenic differentiation in late-stage cells                           | 2           |
| [39]                         |                     |         |                                          |                                               | †Col1, Tn-C, Tnmd, Scx at 0.5 Hz, 4%                                    |             |
| Mechanical stretching        | In vitro            | Rat     | TDSCs in a P(LLA-CL)/Col scaffold        | /                                             | Help maintain the Scx and matrix expression                             | 2           |
| [83]                         |                     |         |                                          |                                               | †Col1f, Col3, and Tn-C at 10%, 1 Hz                                     |             |
| Mechanical stretching        | In vitro            | Human   | BMSC-seeded collagen gel                 | /                                             |                                                                          |             |
| [29]                         |                     |         |                                          |                                               |                                                                          |             |
| Mechanical stretching        | In vitro            | Human   | BMSC encapsulated in poly(ethylene glycol)-based hydrogel material | /                                             |                                                                          |             |
| [88]                         |                     |         |                                          |                                               |                                                                          |             |
| Mechanical stretching        | In vitro            | Mice    | Tenocytes or MDC seeded on PGA           | /                                             | †Mature collagen structure, thicker collagen fibrils, mechanical properties, †Tnmd in MDC-seeded group | 3           |
| [89]                         |                     |         |                                          |                                               | †ECM markers and Mmp13 and Mmp14 at 8%                                  |             |
| Mechanical stretching        | In vitro            | Human   | TPCS                                     | /                                             |                                                                          | 2           |
| [85]                         |                     |         |                                          |                                               |                                                                          |             |
| Mechanical stretching        | In vitro            | Rat     | BMSC seeded in bioactive bFGF-releasing ultrafine PLGA fibres | /                                             | †Scx expression at 5%, 0.5 Hz                                          | 2           |
| [84]                         |                     |         |                                          |                                               |                                                                          |             |
| Biomaterial Scaffold         |                     |         |                                          |                                               |                                                                          |             |
| Poly (L-lactic acid) nanofibres [91] | In vitro & in vivo | Human  | TPCS seeded in aligned scaffold         | Implanted subcutaneously into the dorsal surface of nude mice             | †Scx, †Runx2, and ALP expression in aligned group; more collagen production in vivo in aligned group | 3           |
| Ultrafine PLGA fibres [93]   | In vitro            | Rabbit  | BMSC seeded in bioactive bFGF-releasing ultrafine PLGA fibres | /                                             | †Col1, Fbn, and Bgn; mechanical properties                              | 2           |
| Electrochemically aligned collagen [94] | In vitro | Human  | BMSCs seeded in ELAC                      | /                                             |                                                                          | 2           |
| Fibrin or collagen hydrogels [95] | In vitro          | Mice    | TPCSs seeded in collagen or fibrin hydrogels | /                                             |                                                                          | 2           |
| Collagen-GAG                  | In vitro            | Equine  | Tenocytes seeded in scaffolds            | /                                             |                                                                          | 2           |

Y. Liu et al.
| Material / Method                                                                 | Model | Condition | Cells / Treatment | Expected Outcome                                                                 |
|--------------------------------------------------------------------------------|-------|-----------|-------------------|----------------------------------------------------------------------------------|
| Collagen-polydioxanone sheath [97]                                             | Rabbit | In vivo   |                  | Achilles tendon defect                                                           |
| RGD-coupled alginate microspheres [98]                                         | Human  | In vitro & in vivo | TGF-β3-loaded RGD-coupled alginate microspheres encapsulating PDLCs | Peritendinous adhesion and diameter, density, and alignment of the collagen fibrils |
| Magnetic nanoparticles [99]                                                    | Human  | In vitro & in vivo | ADSC culture on sophisticated magnetic polymer scaffolds | Subcutaneous implantation |
| Decellularized matrix Patellar tendons [102]                                   | Rabbit | In vitro & in vivo | Human TDSC seeded | Implantation in nude rat |
| Tendons [101]                                                                  | Porcine | In vitro & in vivo | Human TPCs seeded | Achilles tendon reconstruction |
| Achilles tendon [103]                                                          | Bovine | In vitro   | Human ADSC culture in collagen scaffold under mechanical stimulation | Preserve the stemness of TDSCs; Tnmd, Col1, Col3; promote neotendon formation |
| Superficial digital flexor tendon [104]                                        | Equine | In vitro   | Equine BMSC seeded in and under moderate mechanical stimulation | ▶ Scx, Tn-C after 24 h mechanical stimulation |
| Superficial digital flexor tendon [105]                                        | Calves | In vitro   | Human ADSCs with TGF-β3 treatment seeded | ▶ Scx, Tn-C |
| Coculture BMSC & TDSC [106]                                                    | Rat    | In vitro & in vivo | Ratio at 1:1 | Patellar tendon defect |
| BMSC & TDSC [107]                                                              | Canine | In vitro   | Raito at 1:1 | / |
| BMSC % autologous ACL cells [108]                                              | Pigs   | In vitro   | Ratio at 1:1 | / |
| ADSC & TDSC [109]                                                              | Human  | In vitro   | Ratio at 3:1 | / |
| Induced pluripotent stem cell [110]                                            | Human  | In vivo    | IPSC-NCSCs suspended in fibrin gel | Scaffold transplanted into patellar tendon defect |

(continued on next page)
Table 1 (continued)

| Factor | Study types | Species | Injury model | Cell model | Study level | Effects |
|--------|-------------|---------|--------------|------------|-------------|---------|
| iPSC-derived MSCs | in vitro | Human | Seeded onto aligned ultrafine fibres | COL and COLA1; promote the maturation of repaired tendon | 3 | Cells shown elongated; Scx and COLA1; promote the maturation of repaired tendon |
| iPSC-derived MSCs | in vivo | Human | In situ rat, Achilles tendon repair | | | |

1. Papers studying the mRNA or protein expression of ECM proteins such as Col1, Col3, Tenomodulin in that are related but not very specific for tendons (e.g., Scx, Scleraxis, BMP, biglycan, BMP Smad2/3 signalling pathway [81]). Gradual or temporary loss of mechanical stimulation would cause a loss of Scx expression, indicating that it can help maintain the Scx expression level [29,81]. The moderate intensity (such as 4% elongation, 0.5–1 Hz) was mostly shown to promote tenogenic differentiation by promoting matrix production [82], and Scx expression when seeded in collagen scaffold [83] or pretreated with BMP12 [84]. Intensive mechanical loading (8% elongation) would help promote further ECM formation [85], and may also promote osteogenic differentiation [82,86,87]. This may also have a relationship with the production of calcified tissues in patients with tendinopathy. Considering the tendon tissue engineering, the mechanical stimulation applied on stem cell-seeded collagen scaffold [29] or hydrogel [88] was also reported to promote tenogenic differentiation by producing mature collagen with thicker fibrils and strong mechanical properties [89].

Collectively, mechanical stimulation plays an essential role during tenogenic differentiation, especially in the late stage, to induce collagen maturation. The intensity of loading is important for the maintenance of tendon property; moderate intensity could help promote ECM and Scx expression, while intensive intensity would lead to osteogenic differentiation, as reported in some studies. For clinical applications, the mechanical loading applied on the stem cell-seeded biomaterials may have the potential to produce tendon-like tissue in the future.

Dynamic mechanical stimulation

Apart from the biological factors, differentiation of embryonic tendon progenitor cell is also regulated by mechanical stimulation in vivo [33]. Formation of immature tendon tissue is possible in the absence of biomechanical stimulation, but advanced differentiation of tendinous tissue requires dynamic stimulation [33,39]. Mechanical stimulation could regulate the release of TGF-β from ECM, which maintains the Scx expression through the TGF-β/Smad2/3 signalling pathway [81]. Gradual or temporary loss of mechanical stimulation would cause a loss of Scx expression, indicating that it can help maintain the Scx expression level [29,81]. The moderate intensity (such as 4% elongation, 0.5–1 Hz) was mostly shown to promote tenogenic differentiation by promoting matrix production [82], and Scx expression when seeded in collagen scaffold [83] or pretreated with BMP12 [84]. Intensive mechanical loading (8% elongation) would help promote further ECM formation [85], and may also promote osteogenic differentiation [82,86,87]. This may also have a relationship with the production of calcified tissues in patients with tendinopathy. Considering the tendon tissue engineering, the mechanical stimulation applied on stem cell-seeded collagen scaffold [29] or hydrogel [88] was also reported to promote tenogenic differentiation by producing mature collagen with thicker fibrils and strong mechanical properties [89].

Collectively, mechanical stimulation plays an essential role during tenogenic differentiation, especially in the late stage, to induce collagen maturation. The intensity of loading is important for the maintenance of tendon property; moderate intensity could help promote ECM and Scx expression, while intensive intensity would lead to osteogenic differentiation, as reported in some studies. For clinical applications, the mechanical loading applied on the stem cell-seeded biomaterials may have the potential to produce tendon-like tissue in the future.

Biomaterials of scaffold and decellularized matrix

Scaffold

The application of novel biomimetic scaffold materials (biological or synthetic origin) is a good strategy for tendon tissue engineering, especially for patients with large tendon defects [90]. The printed modified polymicrofibres or nanofibres or collagen-based hydrogels are the common scaffolds for tendon tissue engineering. It indicated that aligned nanofibres could provide a better microenvironment for stem cells to attach compared with random nanofibres, as evidenced by the cells showing a more elongated shape with increased Scx and ECM marker expression [91,92]. As per in vivo studies, implantation of the scaffold could help promote the maturation of repaired tendon.
tendon with more collagen formation and increased mechanical properties, compared with cells only. Particularly the nanofibre scaffold that can slow down the release of the growth factor, such as FGF2, would have advanced effects on tenogenic differentiation [93]. By contrast, the collagen-based hydrogel is also a good scaffold for tissue engineering, by increasing the Scx and ECM expression when seeded with BMSCs or tendon stem cells [94–97]. Oryan et al [97] reported that collagen-polydioxanone sheath implants could increase new tendon formation with increased diameter, density, and alignment of the collagen fibrils in a rabbit tendon defect model. A codelivery system, TGF-β3-loaded arginine–glycine–aspartic acid tripeptide-coupled alginate microsphere encapsulating the tendon stem cells, could also promote neotendon formation [98]. Novel material, such as magnetic nanoparticles, is also reported to promote Tn-C and Col1 expression in ASCs (Adipose-Derived Stem Cells) [99].

Decellularized matrix

In recent years, the decellularized matrix has become a popular alternative for tendon tissue engineering. With the advantage of its biological origin, it can provide the microenvironment with rich ECM proteins for stem cell niches [100].

Currently, the most popular use of the decellularized matrix is to seed stem cells (such as tendon stem cells, adipose stem cells, Etc.) onto it, to provide the microenvironment for stem cell attachment. Comparing with the decellularized matrix from other origins (e.g., bone and cartilage), the tendon-derived decellularized matrix showed better effects on tenogenic differentiation and also inhibited osteogenetic differentiation [101]. According to in vivo studies, the stem cell-seeded decellularized matrix implants could form tendon-like tissue, with mature collagen fibrils and increased mechanical properties [101,102]. Particularly combining the stem cell-seeded decellularized matrix with mechanical stimulation [103,104] or TGF-β1 treatment [105] was also reported to promote Scx and tendon ECM marker expression, compared with the stem cell-seeded decellularized matrix alone.

In summary, scaffolds such as nanofibres or collagen-based hydrogel and decellularized matrix are potential alternatives for tendon tissue engineering, as they can support the microenvironment for stem cell niches. Nanofibres with alignment or the decellularized matrix derived from tendon showed better effects compared with others. Furthermore, growth factors or mechanical stimulation can also be applied when using the scaffold for tendon regeneration.

Coculture

Considering the limited cell source of TDSCs, some studies also indicated the positive effects of coculturing TDSCs with BMSCs, adipose-derived stem cells, or muscle-derived cells on tenogenic differentiation. Wu et al [106] demonstrated the advantage of coculture of TDSCs with BMSCs at 1:1 ratio with significantly upregulated tenogenic gene marker expression (Tnmd, Scx, Tn-C, and Dcn) and collagen matrix production, and also enhanced tendon injury healing. Schneider et al [107] and Canseco et al [108] also showed similar results. Moreover, the coculture of TDSCs with ASCs at 1:3 ratio was also reported to promote expression of tenogenic genes, such as Tn-C and Scx [109]. Current studies suggested that BMSCs and TDSCs at 1:1 ratio may be a better cell source for tendon tissue engineering.

Induced pluripotent stem cells

As iPSCs have the unique properties of self-renewal and differentiation to many types of cell lineage, these also are an ideal cell source for tissue engineering. Studies found that human iPSC-derived neural crest stem cells could help in tendon repair by transplanting the fibrin gel with cells seeded in a rat patellar tendon defect model [110]. The application of iPSC-induced MSC on aligned ultrafine fibres also showed increased Scx and Col1 expression, and produced mature collagen during tendon repair [92]. For clinical translation, iPSCs are suggested to be a promising cell source, as these are relatively easy to isolate from patients. However, there are still some limitations associated with iPSC application. It is of concern that the basal reprogramming factors may cause other diseases as well, for example, c-Myc plays an important role in the formation of most human cancers [111]. Currently, we are still at the beginning to prove the concept of application of iPSCs in tendon tissue engineering; there is still a long way to go to translate iPSCs into clinical applications.

Clinical applications of stem cells for tendon injuries

Effects of clinical treatments on tendon injuries, such as tendinopathy or tendon rupture, are limited. Normal healing of tendon injuries is prolonged, due to the limited self-regenerative ability and poor vascularity of tendon tissues [30]. The application of cell therapies (e.g., autologous tenocytes, fibroblast, or autologous BMSCs) for the treatment of tendon injuries has been conducted in clinical trials in recent years and summarized by Ho et al [112]. Although the authors indicated that tendon healing was promoted using cell therapy, the studies are limited by nonrandomized and short-term clinical follow-up and thus unable to indicate its long-term effects for injury healing.

Recently, a 4.5-year clinical follow-up study with application of autologous tenocyte injection was reported to promote healing in patients with chronic resistant lateral epicondylitis [113,114]. Briefly, the authors isolated autologous tenocytes from patellar tendon needle biopsy and expanded cells in vitro. Then the autologous tenocytes were injected into the site with tendinopathy under ultrasound guidance. During the 4.5-year clinical follow-up, the results showed increased function recovery in lateral epicondylitis patients, with decreased pain and an increased range of motion at arm, shoulder, and hand [114]. No complications were observed in any patient, indicating that autologous tenocyte injection is relatively safe. Meanwhile, a case report using the autologous tenocyte injection for the
treatment of a 20-year-old elite gymnast with a rotator cuff tendon injury was also reported by the same group [115]. The partial-thickness tear was healed by magnetic resonance imaging observation in 1-year follow-up. The patient reported substantial improvement of clinical symptoms and was able to return to national-level competition. Moreover, Lee et al [116] reported that injection of allogeneic adipose-derived stem cells mixed with fibrin glue can also improve the performance of patients with lateral epicondylitis through 52 weeks of follow-up. The application of bone marrow containing both plasma with rich growth factors and BMSCs was also reported to improve function recovery in patients with tennis elbow in a 12-week clinical follow-up [117]. However, the limitations of the study are a small number of participants and absence of a control group.

The overall results indicated the therapeutic value of stem cell (TDSCs or BMSCs) injection for tendinopathy, which is relatively safe (Table 2). There are no reported safety issues with using the autologous cell therapy currently. However, some problems still need to be considered for its future clinical applications. Most current clinical trials are limited by a small number of participants, lack of control group, or short-term follow-up. Well-designed, nonrandomized, long-term studies with enough

| Cell source | Injury type | Patient no. | Type of treatment & study | Outcome measure | Effects | Level of evidencea |
|-------------|-------------|-------------|---------------------------|-----------------|---------|-------------------|
| Autologous tenocyte [113,114] | Chronic lateral epicondylitis | 15 | Ultrasound-guided injection | VAS score, QuickDASH, UEFS, grip strength, MRI scanning | Improved clinical function and MRI tendinopathy scores in 4.5-y follow-up; no complications observed at the patellar tendon biopsy site for any patient | 4 |
| Autologous tenocyte [115] | Rotator cuff (case report) | 1 | Ultrasound-guided injection | VAS, QuickDASH, Oxford shoulder score, MRI | Reduced pain; partial-thickness tear healed on MRI; back to national-level competition | 4 |
| Allogeneic ADSCs [116] | Chronic lateral epicondylitis | 12 | Mixed with fibrin glue injection | VAS, modified Mayo clinic performance index for elbow, ultrasound images of tendon defect | Improved elbow performance and pain; defect decrease observed under ultrasound | 4 |
| Bone marrow aspirateb [117] | Tennis elbow | 30 | Direct injection | PRTEE | Decreased PRTEE in 1-y follow-up | 4 |

ADSC = adipose-derived stem cells; MRI = magnetic resonance imaging; PRTEE = patient-rated tennis elbow evaluation; Quick-DASH = quick disabilities of the arm, shoulder and hand; UEFS = Upper Extremity Functional Scale; VAS = visual analogue scale.

a According to the Centre for Evidence Based Medicine (http://www.cebm.net).

b Containing plasma rich in growth factors and mesenchymal stem cells.

Figure 1 Summary of the current understanding and concepts of tenogenic differentiation. ADSC = adipose-derived stem cell; BMSC = bone marrow stem cell; CTGF = connective tissue growth factor; FGF = fibroblast growth factor; GDF = growth differentiation factor; ERK: Extracellular signal–regulated kinases; iPSC = induced pluripotent stem cell; TGF-β = transforming growth factor β.
participants (both treatment and control) are needed to confirm its healing effects. Moreover, as stem cells such as TDSCs or BMSCs were all reported to show multipotent differentiation abilities [31,32], as well as tumorigenesis [118], more long-term well-designed randomized controlled trials are still needed to confirm its safety with respect to nonneoptopic bone formation or tumour formation. Apart from that, application of rhBMP12 has been shown to be relatively safe and effective in patients with rotator cuff in clinical trials [66]. Injection of BMP12-pretreated TDSCs or BMSCs may have advanced effects on repaired tendon healing [66], as it may avoid the potential of nonotenogenic differentiation of injected stem cells. This is warranted to be considered for future applications.

Conclusion

The understanding of tenogenic differentiation has greatly improved and broadened in recent 10 years. As summarized in this review, current experimental data support the strategies of applying growth factors (especially TGF-β, GDF5/7, and CTGF), moderate mechanical stimulation, biomaterials (fibres with alignment or tendon-derived decellularized matrix), coculture of BMSCs and TDSCs at 1:1 ratio showed promising effects on promoting tenogenic differentiation of stem cells (TDSCs or BMSCs) (Figure 1). However, a lack of consensus on tendon-specific markers led to challenges regarding assessing the efficacy of strategies for tenogenic differentiation; the discovery of specific markers will undoubtedly help identify a novel therapeutic approach. On the contrary, the development of tendon relies on both biological and biomechanical stimulation [6,30]; applications of the growth factor or biomaterials in combination with mechanical stimulation will be the future directions for tendon tissue engineering.

However, there is still a large gap between experimental research and clinical applications. For tendon injury healing, current clinical trials are limited to the usage of stem cells (TDSCs or BMSCs) only for the treatment of tendonopathy, and most of the current strategies for tenogenic differentiation are still in the preclinical stage, because of the high standard of safety requirements for clinical trials in contrast to the experimental research work [112]. To translate the current findings to clinical applications, we need to pay attention to their safety (e.g., stem cell or growth factor treatment for tendon adhesion [41], potential nonneoptopic bone formation [119], or tumour formation [118]), and long-term follow-up with enough participants (both treatment and control) in nonrandomized studies. Experimental work has found that pretreated BMSCs or TDSCs with growth factors (such as BMP12 and CTGF) promotes tenogenic differentiation and inhibits osteogenic differentiation, whereas application of biomaterials seeded with BMSCs or TDSCs facilitates their adhesion and survival. To translate these findings from bench to clinical settings, using these new strategies in patients with tendon injuries is warranted.

Conflicts of interest

The authors indicate no potential conflicts of interest.

Acknowledgements

The work was partially supported by grants from National Natural Science Foundation of China (81371946 and 81374568); Hong Kong Government Research Grant Council, General Research Fund (470813, 14119115, and 9054014); and grants from China Shenzhen City Science and Technology Bureau (GJHZ20140419120051680 and JCYJ20150630165236960). This study was also supported in part by SMART program, Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, and the research was made possible by resources donated by Lui Che Woo Foundation Limited.

References

[1] Duquin TR, Buyea C, Bisson LJ. Which method of rotator cuff repair leads to the highest rate of structural healing? A systematic review. Am J Sports Med 2010;38:835–41.
[2] Gulati V, Jaggard M, Al-Namari SS, Uzoigwe C, Gulati P, Ismail N, et al. Management of achilles tendon injury: a current concepts systematic review. World J Orthop 2015;6:386–9.
[3] Sharma P, Maffulli N. Tendon injury and tendinopathy: healing and repair. J Bone Joint Surg Am 2005;87:187–202.
[4] Shearn JT, Kinneberg KR, Dyment NA, Galloway MT, Kenter K, Wylie C, et al. Tendon tissue engineering: progress, challenges, and translation to the clinic. J Musculoskeletal Neuronal Interact 2011;11:163–73.
[5] Bi Y, Ehirchiou D, Khits TM, Inkson CA, Embree MC, Sonoyama W, et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med 2007;13:1219–27.
[6] James R, Kesturu G, Ballan G, Chhabra AB. Tendon: biology, biomechanics, repair, growth factors, and evolving treatment options. J Hand Surg Am 2008;33:102–12.
[7] Chiodo CP, Wilson MG. Current concepts review: acute ruptures of the Achilles tendon. Foot Ankle Int 2006;27:305–13.
[8] Josza L, Lehto M, Kannus P, Kvist M, Reffy A, Vieno T, et al. Fibronectin and laminin in Achilles tendon. Acta Orthop Scand 1989;60:469–71.
[9] Ito Y, Toriuchi N, Yoshihata T, Ueno-Kudoh H, Sato T, Yokoyama S, et al. The Mohawk homeobox gene is a critical regulator of tendon differentiation. Proc Natl Acad Sci USA 2010;107:10538–42.
[10] Galloway MT, Lailey AL, Shearn JT. The role of mechanical loading in tendon development, maintenance, injury, and repair. J Bone Joint Surg Am 2013;95:1620–8.
[11] Rui YF, Lui PP, Wong YM, Tan Q, Chan KM. BMP-2 stimulated non-tenogenic differentiation and promoted proteoglycan deposition of tendon-derived stem cells (TDSCs) in vitro. J Orthop Res 2013;31:746–53.
[12] Zhang G, Ezura Y, Chervoneva I, Robinson PS, Beason DP, Carine ET, et al. Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. J Cell Biochem 2006;98:1436–49.
[13] Dunkman AA, Buckley MR, Mienaltowski MJ, Adams SM, Thomas SJ, Satchell L, et al. The tendon injury response is influenced by decorin and biglycan. Ann Biomed Eng 2014;42:619–30.
[14] Chakravarti S. Functions of lumican and fibromodulin: lessons from knockout mice. Glycocon J 2002;19:287–93.
[15] Riley GP, Harrall RL, Cawston TE, Hazleman BL, Mackie EJ, Tenascin-C and human tendon degeneration. Am J Pathol 1996;149:933–43.
[16] Mehr D, Pardubsky PD, Martin JA, Buckwalter JA. Tenascin-C in tendon regions subjected to compression. J Orthop Res 2000;18:535–47.

[17] Brandau O, Meindl A, Fassler R, Aszödi A. A novel gene, tendin, is strongly expressed in tendons and ligaments and shows high homology with chondromodulin-I. Dev Dyn 2001;221:72–80.

[18] Docheva D, Hunziker EB, Fassler R, Brandau O. Tenomodulin is necessary for tenocyte proliferation and tendon maturation. Mol Cell Biol 2005;25:699–705.

[19] Shukunami C, Takimoto A, Oro M, Hiraki Y. Scleraxis positively regulates the expression of tenomodulin, a differentiation marker of tenocytes. Dev Biol 2006;298:234–47.

[20] Murchison ND, Price BA, Conner DA, Keene DR, Olson EN, Tabin CJ, et al. Regulation of tendon differentiation by scleraxis distinguishes force-transmitting tendons from muscle-anchoring tendons. Development 2007;134:2697–708.

[21] Guerquin MJ, Charvet B, Nourissat G, Havis E, Ronson O, Bonnin MA, et al. Transcription factor EGR1 directs tendon differentiation and promotes tendon repair. J Clin Invest 2013;123:3567–76.

[22] Brent AE, Schwetizer R, Tabin CJ. A somitic compartment of tendon progenitors. Cell 2003;113:233–48.

[23] Brent AE, Tabin CJ. FGF acts directly on the somitic tendon progenitors through the Ets transcription factors PEA3 and ERM to regulate scleraxis expression. Development 2004;131:3885–96.

[24] Schwetizer R, Chyung JH, Murtaugh LC, Brent AE, Rosen V, Olson EN, et al. Analysis of the tendon cell fate using Scleraxis, a specific marker for tendons and ligaments. Development 2001;128:3855–66.

[25] Lejard V, Brideau G, Blais F, Salingcarnboriboon R, Wagner G, Roehrl MH, et al. Scleraxis and Nfatc regulate the expression of the pro-alpha1(I) collagen gene in tendon fibroblasts. J Biol Chem 2007;282:17665–75.

[26] Milet C, Duprez D. The Mkk homeoprotein promotes tenogenesis in stem cells and improves tendon repair. Ann Transl Med 2015;3(10):1-11.

[27] Liu H, Zhang C, Zhu S, Lu P, Zhu T, Gong X, et al. Mohawk as a differentiation marker of tenocytes. Dev Biol 2006;298:234–47.

[28] Lejard V, Blais F, Guerquin MJ, Bonnet A, Bonnin MA, Havis E, et al. EGR1 and EGR2 involvement in vertebrate tendon differentiation. J Biol Chem 2011;286:5855–67.

[29] Kuo CK, Tuan RS. Mechanoactive tenogenic differentiation of human mesenchymal stem cells. Tissue Eng Part A 2008;14:1615–27.

[30] Nourissat G, Berenbaum F, Duprez D. Tendon injury: from biology to tendon repair. Nat Rev Rheumatol 2015;11:223–33.

[31] Rui YF, Lui PP, Li G, Fu SC, Lee YW, Chan KM. Isolation and characterization of multipotent rat tendon-derived stem cells. Tissue Eng Part A 2010;16:1549–58.

[32] Tan Q, Lui PP, Rui YF, Wong YM. Comparison of potentials of stem cells isolated from tendon and bone marrow for musculoskeletal tissue engineering. Tissue Eng Part A 2012;18:840–51.

[33] Lorda-Diez CI, Montero JA, Garcia-Porrero JA, Hurle JM. Divergent differentiation of skeletal progenitors into cartilage and tendon: lessons from the embryonic limb. ACS Chem Biol 2014;9:72–9.

[34] Lui PP, Rui YF, Ni M, Chan KM. Tenogenic differentiation of stem cells for tendon repair: what is the current evidence? J Tissue Eng Regen Med 2015;5:e144–63.

[35] Havis E, Bonnin MA, Olivera-Martinez I, Nazaret N, Ruggiu M, Weibel J, et al. Transcriptomic analysis of mouse limb tendon cells during development. Development 2014;141:3683–96.

[36] Chhabra A, Tsou D, Clark RT, Gaschen V, Hunziker EB, Mikic B. GDF-5 deficiency in mice delays Achilles tendon healing. J Orthop Res 2003;21:826–35.

[37] Francis-West PH, Parish J, Lee K, Archer CW. BMP/GDF-signalling interactions during synovial joint development. Cell Tissue Res 1999;296:111–9.

[38] Pryce BA, Watson SS, Murchison ND, Staverosky JA, Dünker N, Schwetizer R. Recruitment and maintenance of tendon progenitors by TGF-beta signaling are essential for tendon formation. Development 2009;136:1351–61.

[39] Brown JP, Finley VG, Kuo CK. Mechanical and soluble cues regulate tendon progenitor cell gene expression as a function of developmental stage and anatomical origin. J Biomech 2014;47:214–22.

[40] Yin Z, Guo J, Wu TY, Chen X, Xu LL, Lin SE, et al. Stepwise differentiation of mesenchymal stem cells augment tendons-like tissue formation and defect repair in vivo. Stem Cells Transl Med 2016;5:1106–16.

[41] Klein MB, Yalamanchi N, Pham H, Longaker MT, Chang J. Flexor tendon healing in vitro: effects of TGF-beta on tendon cell collagen production. J Hand Surg Am 2002;27:615–20.

[42] Berthet E, Chen C, Butcher K, Schneider RA, Alliston T, Amirzargarah M. Smad3 binds Scleraxis and Mohawk and regulates tendon matrix organization. J Orthop Res 2013;31:1475–83.

[43] Katzel EB, Wolenski M, Loiselle AE, Basile P, Flick LM, Langstein HN, et al. Impact of Smad3 loss of function on scarring and adhesion formation during tendon healing. J Orthop Res 2011;29:684–93.

[44] Cohn MJ, Izpisua-Belmonte JC, Abud H, Heath JK, Tickle C. Fibroblast growth factors induce additional limb development from the flank of chick embryos. Cell 1995;80:739–46.

[45] Brent AE, Braun T, Tabin CJ. Genetic analysis of interactions between the somitic muscle, cartilage and tendon cell lineages during mouse development. Development 2005;132:515–28.

[46] Wasterlain AS, Braun HJ, Harris AH, Kim HJ, Dragoo JL. The systemic effects of platelet-rich plasma injection. Am J Sports Med 2013;41:186–93.

[47] Hankemeier S, Keus M, Zeichen J, Jagodzinski M, Christen P, Berthet E. Expression of scleraxis and tenascin C families during mouse development. Development 2005;132:4523–34.

[48] Reed SA, Johnson SE. Expression of scleraxis and tenascin C in equine adipose and umbilical cord blood derived stem cells is dependent upon substrata and FGF supplementation. Cytotherapy 2014;16:27–35.

[49] Tang JB, Wu YF, Cao Y, Chen CH, Zhou YL, Avanessian B, et al. Basic FGF or VEGF gene therapy corrects insufficiency in the intrinsic healing capacity of tendons. Sci Rep 2016;6:20643.

[50] Buchmann S, Sandmann GH, Walz L, Hoppe H, Beitzel K, Wexel G, et al. Refixation of the supraspinatus tendon in a biodegradable matrix. J Orthop Res 2003;21:826–35.

[51] Ker ED, Chu B, Phillippi JA, Gharabeb B, Huard J, Weiss LE, et al. Bioprinting of growth factors onto aligned sub-micron fibrous scaffolds for simultaneous control of cell differentiation and alignment. Biomaterials 2011;32:8097–107.

[52] Ide J, Kikukawa K, Hirose J, Iyama K, Sakamoto H, Fujimoto T, et al. The effect of a local application of fibroblast growth factor-2 on tendon-to-bone remodeling in rats.
with acute injury and repair of the supraspinatus tendon. J Shoulder Elbow Surg 2009;18:391–8.

[54] Ide J, Kikukawa K, Hirose J, Iyama K, Sakamoto H, Mizuta H. The effects of fibroblast growth factor-2 on rotator cuff repair with acellular dermal matrix grafts. Arthroscopy 2009;25:608–16.

[55] Tokunaga T, Shukunami C, Okamoto N, Taniwaki T, Oka K, Sakamoto H, et al. FGF-2 stimulates the growth of tenogenic progenitor cells to facilitate the generation of tenomodulin–positive tenocytes in a rotator cuff healing model. J Am Sports Med 2015;43:2411–22.

[56] Wolfman NM, Hattersley G, Cox K, Celeste AJ, Nelson R, Clark RT, Johnson TL, Schalet BJ, Davis L, Gaschen V, Hunziker EB. GDF-5 deficiency in mice leads to developmental and end-stage phenotypes in GDF6 deficient mice. Anat Rec (Hoboken) 2009;324:396.

[57] Lee CH, Shah B, Moioli EK, Mao JJ. CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. J Clin Invest 2010;120:3340–9.

[58] Liu J, Tao X, Chen L, Han W, Zhou Y, Tang K. CTGF positively regulates BMP12 induced tenogenic differentiation of tendon stem cells and signaling. Cell Physiol Biochem 2015;35:1831–45.

[59] Lee CH, Lee FY, Tatarfber S, Kao K, Jun Y, Yang G, et al. Harnessing endogenous stem/progenitor cells for tendon regeneration. J Clin Invest 2015;125:2690–701.

[60] Maeda T, Sakabe T, Sunaga A, Sakai K, Rivera AL, Keene DR, et al. The role of scleraxis in fate determination of mesenchymal stem cells and signaling. Cell Physiol Biochem 2015;36:517–30.

[61] Greiner S, Ide J, Van Noort A, Mochizuki Y, Ochi H, Marraffino S, et al. Local rhBMP-12 on an absorbable collagen sponge as an adjuvant therapy for rotator cuff repair—a phase 1, randomized, standard of care control, multicenter study: safety and feasibility. Am J Sports Med 2015;43:1994–2004.

[62] Jelinsky SA, Li L, Ellis D, Archambault J, Li J, St Andre M, et al. Treatment with rhBMP12 or rhBMP13 increase the rate and the quality of rat Achilles tendon repair. J Orthop Res 2011;29:1604–12.

[63] Gulotta LV, Kovacevic D, Packer JD, Enteshami JR, Rodeo SA. ADAM10 mediates gene transfer of human bone morphogenetic protein-13 does not improve rotator cuff healing in a rat model. Am J Sports Med 2011;39:180–7.

[64] ten Berge D, Brugmann SA, Helms JA, Nusse R. Wnt and FGF signals interact to coordinate growth with cell fate specification during limb development. Development 2008;135:3247–57.
Yang G, Rothrauff BB, Lin H, Gottardi R, Alexander PG, Tuan RS. Induction of tenogenic differentiation mediated by extra-cellular tendon matrix and short-term cyclic stretching. Stem Cells Int 2016;2016:7342379.

Yang G, Rothrauff BB, Lin H, Yu S, Tuan RS. Tendon-derived extracellular matrix enhances transforming growth factor-beta3-induced tenogenic differentiation of human adipose-derived stem cells. Tissue Eng Part A 2017;23:166–76.

Yang G, Wang B, Sun Y, Xu J, Yik-Wai LW, et al. The use of cocultured mesenchymal stem cells with tendon-derived stem cells as a better cell source for tendon repair. Tissue Eng Part A 2016;22:1229–40.

Yin Z, Chen X, Lu P, Zhu T, et al. The regulation of tendon stem cell differentiation by the alignment of nanofibers. Biomaterials 2010;31:2163–75.

Zhang C, Yuan H, Liu H, Chen X, Lu P, Zhu T, et al. Well-aligned chitosan-based ultrafine fibers committed teno-lineage differentiation of human induced pluripotent stem cells for Achilles tenotomy regeneration. Biomaterials 2015;53:716–30.

Zahoor S, Toh SL, Goh JC. A bFGF-releasing silk/PLGA-based biohybrid scaffold for ligament/tendon tissue engineering using mesenchymal progenitor cells. Biomaterials 2010;31:2990–8.

Kishore V, Bullock W, Sun X, Van Dyke WS, Akkus O. Tenogenic differentiation of human MSCs induced by the topography of electrochemically aligned collagen threads. Biomaterials 2012;33:2137–44.

Breidenbach AP, Dyment NA, Lu Y, Rao M, Shearn JT, Rowe DW, et al. Fibrin gels exhibit improved biological, structural, and mechanical properties compared with collagen gels in cell-based tendon-tissue-engineered constructs. Tissue Eng Part A 2015;21:438–50.

Callari SR, Weisgerber DW, Ramirez MA, Kelkhoff DO, Harley BA. The influence of collagen-glycosaminoglycan scaffold relative density and microstructural anisotropy on tenocyte bioactivity and transcriptomic stability. J Mech Behav Biomed Mater 2012;11:27–40.

Oryan A, Moshiri A, Parizi AM, Maffulli N. Implantation of a novel biologic and hybridized tissue engineered bioimplant in large tendon defect: an in vivo investigation. Tissue Eng Part A 2014;20:447–65.

Moshaverinia A, Xu X, Chen C, Ansari S, Zadeh HH, Snead ML, et al. Application of stem cells derived from the periodontal ligament or gingival tissue sources for tendon tissue regeneration. Biomaterials 2014;35:2642–50.

Goncalves AI, Rodrigues MT, Carvalho PP, Bañobre-López M, Paz E, Freitas P, et al. Exploring the potential of starch/polycaprolactone aligned magnetic responsive scaffolds for tendon regeneration. Adv Healthc Mater 2016;5:213–22.

Lovati AB, Bottagisio M, Morelli M. Decellularized and engineered tendons as biological substitutes: a critical review. Stem Cells Int 2016;2016:7276150.

Yin Z, Chen X, Zhu T, Hu JJ, Song HX, Shen WL, et al. The effect of decellularized matrices on human tendon stem-/progenitor cell differentiation and tendon repair. Acta Biomater 2013;9:9317–29.

Zhang J, Li B, Wang JH. The role of engineered tendon matrix in the stemness of tendon stem cells in vitro and the promotion of tendon-like tissue formation in vivo. Biomaterials 2011;32:6972–81.

Yang G, Rothrauff BB, Lin H, Gottardi R, Alexander PG, Tuan RS. Enhancement of tenogenic differentiation of human adipose stem cells by tendon-derived extracellular matrix. Biomaterials 2013;34:9295–306.